Crinetics Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
437
- Stock Symbol
-
CRNX
- Investments
-
1
- Share Price
-
$30.85
- (As of Tuesday Closing)
Crinetics Pharmaceuticals General Information
Description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Contact Information
Website
www.crinetics.comCorporate Office
- 6055 Lusk Boulevard
- San Diego, CA 92121
- United States
Corporate Office
- 6055 Lusk Boulevard
- San Diego, CA 92121
- United States
Crinetics Pharmaceuticals Timeline
Crinetics Pharmaceuticals Stock Performance
As of 17-Jun-2025, Crinetics Pharmaceuticals’s stock price is $30.85. Its current market cap is $2.89B with 93.7M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $30.85 | $31.20 | $24.10 - $62.53 | $2.89B | 93.7M | 941K | -$3.82 |
Crinetics Pharmaceuticals Financials Summary
As of 31-Mar-2025, Crinetics Pharmaceuticals has a trailing 12-month revenue of $760K.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,818,501 | 3,931,546 | 1,874,236 | 619,692 |
| Revenue | 760 | 1,039 | 4,013 | 4,737 |
| EBITDA | (373,965) | (337,058) | (226,867) | (167,252) |
| Net Income | (328,252) | (298,408) | (214,529) | (163,918) |
| Total Assets | 1,361,327 | 1,434,592 | 635,353 | 352,176 |
| Total Debt | 50,819 | 51,722 | 51,728 | 3,075 |
Crinetics Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Crinetics Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Crinetics Pharmaceuticals Comparisons
Industry
Financing
Details
Crinetics Pharmaceuticals Competitors (74)
One of Crinetics Pharmaceuticals’s 74 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA |
Crinetics Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Crinetics Pharmaceuticals Patents
Crinetics Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12208092-B2 | Compositions and methods for administering paltusotine to patients with hepatic impairment | Active | 28-Mar-2023 | ||
| US-20240325376-A1 | Compositions and methods for administering paltusotine to patients with hepatic impairment | Active | 28-Mar-2023 | ||
| US-20240208963-A1 | Crystalline melanocortin subtype-2 receptor (mc2r) antagonist | Pending | 16-Dec-2022 | ||
| AU-2023395880-A1 | Crystalline melanocortin subtype-2 receptor (mc2r) antagonist | Pending | 16-Dec-2022 | ||
| US-20240254105-A1 | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof | Active | 13-Dec-2022 | C07D401/14 |
Crinetics Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Crinetics Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Crinetics Pharmaceuticals Investments (1)
Crinetics Pharmaceuticals’s most recent deal was a Early Stage VC with Radionetics Oncology for . The deal was made on 03-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Radionetics Oncology | 03-Jan-2024 | Early Stage VC | Drug Discovery |
Crinetics Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated October, 22, 2024
38.7 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Crinetics Pharmaceuticals FAQs
-
When was Crinetics Pharmaceuticals founded?
Crinetics Pharmaceuticals was founded in 2008.
-
Where is Crinetics Pharmaceuticals headquartered?
Crinetics Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals has 437 total employees.
-
What industry is Crinetics Pharmaceuticals in?
Crinetics Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Crinetics Pharmaceuticals a private or public company?
Crinetics Pharmaceuticals is a Public company.
-
What is Crinetics Pharmaceuticals’s stock symbol?
The ticker symbol for Crinetics Pharmaceuticals is CRNX.
-
What is the current stock price of Crinetics Pharmaceuticals?
As of 17-Jun-2025 the stock price of Crinetics Pharmaceuticals is $30.85.
-
What is the current market cap of Crinetics Pharmaceuticals?
The current market capitalization of Crinetics Pharmaceuticals is $2.89B.
-
What is Crinetics Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Crinetics Pharmaceuticals is $760K.
-
Who are Crinetics Pharmaceuticals’s competitors?
Protagonist Therapeutics, Apellis Pharmaceuticals, Nektar Therapeutics, Abeona Therapeutics, and Gilead Sciences are some of the 74 competitors of Crinetics Pharmaceuticals.
-
What is Crinetics Pharmaceuticals’s annual earnings per share (EPS)?
Crinetics Pharmaceuticals’s EPS for 12 months was -$3.82.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
